NRSN net incomeFY2025-$11.13M
NRSN net income was -$11.13M for fiscal 2025 (ended Dec 31, 2025), compared with -$10.21M in fiscal 2024.
NeuroSense Therapeutics Ltd. (NRSN) financials
For fiscal 2025 (ended Dec 31, 2025), NeuroSense Therapeutics Ltd. reported -$11.13M of net income.
- Net income, FY2025
- -$11.13M
- Free cash flow, FY2025
- -$7.68M
- EPS, diluted, FY2025
- -$0.44
- Cash
- $166.0K
- Market cap
- $3.5M
FY2019FY2025
FY2019FY2025
NRSN revenue and earnings growth
NRSN EPSFY2025-$0.44
NRSN diluted EPS was -$0.44 for fiscal 2025 (ended Dec 31, 2025), compared with -$0.54 in fiscal 2024.
NRSN free cash flowFY2025-$7.68M
NRSN free cash flow was -$7.68M for fiscal 2025 (ended Dec 31, 2025), compared with -$10.14M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Research and development | $6.23M | $5.70M | $7.27M | $5.59M | - | - | - |
| Selling, general and admin | $4.86M | $4.20M | $4.78M | $4.97M | $2.50M | $393.0K | $337.0K |
| Operating income | -$11.09M | -$9.90M | -$12.05M | -$10.55M | -$5.59M | -$2.89M | -$1.24M |
| Interest expense | - | - | $2.21M | $45.0K | $1.19M | $1.0K | $5.0K |
| Net income | -$11.13M | -$10.21M | -$10.11M | -$10.49M | -$4.04M | -$2.83M | -$1.22M |
| EPS, basic | -$0.44 | -$0.54 | -$0.74 | -$0.91 | -$0.65 | -$0.51 | -$0.26 |
| EPS, diluted | -$0.44 | -$0.54 | -$0.74 | -$0.91 | -$0.65 | -$0.51 | - |
| Diluted shares | 25.5M | 18.6M | 13.6M | 11.5M | - | - | - |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $166.0K | $3.38M | $2.64M | $3.54M | $11.06M | $699.0K | $895.0K |
| Current assets | $778.0K | $4.40M | $2.92M | $7.38M | $11.41M | $766.0K | - |
| Total assets | $1.03M | $4.58M | $3.19M | $7.71M | $11.43M | $779.0K | - |
| Current liabilities | $2.52M | $1.99M | $3.46M | $1.73M | $597.0K | $120.0K | - |
| Total liabilities | $2.59M | $1.99M | $4.94M | $2.09M | $2.42M | $120.0K | - |
| Shareholders' equity | -$1.56M | $2.58M | -$1.76M | $5.84M | $10.83M | $659.0K | $918.0K |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.67M | -$10.13M | -$8.35M | -$7.62M | -$1.54M | -$695.0K | -$582.0K |
| Capital expenditures | $8.0K | $3.0K | $29.0K | $70.0K | $17.0K | $9.0K | $7.0K |
| Free cash flow | -$7.68M | -$10.14M | -$8.38M | -$7.69M | -$1.56M | -$704.0K | -$589.0K |
| Investing cash flow | -$8.0K | $1.0K | $3.47M | -$3.59M | -$17.0K | -$9.0K | -$26.0K |
| Financing cash flow | $4.43M | $10.91M | $3.98M | $3.77M | $11.90M | $508.0K | $1.42M |
| Stock-based compensation | $2.14M | $557.0K | $1.54M | $1.73M | $4.16M | $2.06M | $611.0K |
Key ratios
Source: XBRL data NeuroSense Therapeutics Ltd. files with the SEC, latest filing dated Mar 31, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
NRSN peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| NRSN | - | - | -$11.13M | - | $3.5M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
NRSN FAQ
6 questionsIs NRSN profitable?
No. NeuroSense Therapeutics Ltd. reported a net loss of $11.13M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does NRSN have?
NeuroSense Therapeutics Ltd. reported $166.0K in cash and cash equivalents on its most recent balance sheet in SEC filings.What is NRSN free cash flow?
NeuroSense Therapeutics Ltd. generated -$7.68M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$7.67M less capital expenditures.What is NRSN earnings per share?
Diluted earnings per share were -$0.44 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did NRSN last report financial results?
The latest statements here come from NeuroSense Therapeutics Ltd.'s 20-F filed on Mar 31, 2026, covering the period ended Dec 31, 2025.Where does this NRSN financial data come from?
Quantisnow builds these statements from the structured XBRL data NeuroSense Therapeutics Ltd. files with the SEC. It is provided for information only and is not investment advice.